This area is reserved for registered users. Please register or login.

Brintellix (Vortioxetine) ▼ – Indicated for the Treatment of Major Depressive Episodes in Adults

Lundbeck is pleased to announce that Brintellix (vortioxetine), indicated for the treatment of major depressive episodes in adults, is now available in Ireland. It exhibits a unique, multimodal pharmacological profile, modulating serotonin receptor activity and inhibiting serotonin reuptake.   Vortioxetine modulates neurotransmission in a number of systems, including predominantly the serotonin but probably also the noradrenaline, dopamine, histamine, acetylcholine, GABA and glutamate systems. This multimodal activity is considered responsible for the antidepressant effects of vortioxetine, as well as for the improvement in cognitive function, learning and memory observed in animal studies.1   Depression is a complex condition that manifests through…